Latest posts
Merck and Pfizer - Strange bedfellows?
- 30 Apr 2013 09:12
- by Deborah Toscano
- 0 comments (Add comment)
In a surprising announcement made yesterday, Merck and Pfizer are teaming up to commercialize Pfizer’s SGLT2 inhibitor ertugliflozin for diabetes. This announcement took the pharma world by surprise, especially since Merck in particular is not known for forming partnerships with other big pharmas. Typically these partnerships leverage the individ...
Umbilical Cord blood - A savior !
- 30 Apr 2013 04:29
- by Deepika Pramod Chopda
- 2 comments
http://www1.umn.edu/news/features/2013/UR_CONTENT_440332.html ...
Cloud and Mobile Technology Set to End Innovation 'Drought'
- 02 Apr 2013 21:18
- by Andrew Milroy
- 0 comments (Add comment)
It is often stated by senior management figures within large enterprises, that innovation is a key area of focus for them. Despite this focus, the past 50 or 60 years has witnessed a distinct lack of breakthrough innovations. Indeed, there has been an innovation 'drought'. Innovations made between the late nineteenth century and about 1950 are th...
Biosimilars: blockbuster or lackluster?
- 21 Mar 2013 11:48
- by Deborah Toscano
- 0 comments (Add comment)
In follow up to my last blog, as a result of the Omontys recall, Affymax has resorted to a 75 percent reduction in staff in order to stay afloat, and may even be forced into bankruptcy. Although Affymax is a small company who is reliant on this single product, they were forecast to earn peek sales from Omontys in 2018 of approximately $484 million ...
More Calls to End Fee for Service: A Look at Recommendations from the National Commission on Physician Payment Reform
- 18 Mar 2013 15:46
- by Nancy Fabozzi
- 0 comments (Add comment)
“Our nation cannot control runaway medical spending without fundamentally changing how physicians are paid.” The National Commission on Physician Payment Reform, March 2013 In March 2012, the Society of General Internal Medicine (SGIM) assembled an expert commission to look at ways of changing physician reimbursement in order to improve patient ...
Could the U.S. biosimilars market suffer from a recent branded biologic's misfortune?
- 25 Feb 2013 14:59
- by Deborah Toscano
- 0 comments (Add comment)
Affymax’s and Takeda’s biologic drug for anemia, Omontys, is the latest victim of the discovery of serious adverse events in the post-marketing setting. Less than a year after the FDA granted marketing approval, reports of serious anaphylactic reactions, three of which were fatal, prompted the companies to recall the drug. Omontys is a similar drug...
City as a Customer
- 12 Feb 2013 21:30
- by Jinu Mathew
- 0 comments (Add comment)
Written by Archana Vidyasekar and Akshay Gakhar Understanding the Macro to Micro Impact of the Urbanisation Mega Trend and Identifying the Inherent Business Opportunities in Tomorrow's Cities By 2025, the world urban population will reach 4.6 billion and account for 58% of total population. This means that 6 out of 10 people will live in urban ar...
Tools
Blog Archive
- April 2013 (3)
- March 2013 (2)
- Febuary 2013 (3)
- January 2013 (2)
- December 2012 (1)
- November 2012 (1)
- October 2012
- September 2012 (3)
- August 2012 (2)
- July 2012 (5)
- June 2012 (5)
- May 2012 (10)
Help Desk
For more information and general enquiries, contact Frost & Sullivan near you.
Select a location near you..